Modification of a Selective NTRK2 Agonist and Confirmation of Activity in a Glaucoma-on-a-Chip Model.

Fatemeh NafianMozhgan Rezaei KanaviMohammad Javad RasaeeBabak Kamali Doust AzadNarsis DaftarianMozhgan Rezaei Kanavi

Published in: Journal of ophthalmic & vision research (2024)

The modified peptide studied herein showed improved stability over the original peptide (RNYK) and demonstrated potential for use as a BDNF agonist with neuroprotective properties for treatment of neurodegenerative disorders such as glaucoma.

Keyphrases

optic nerve
high throughput
circulating tumor cells
combination therapy
stress induced
cerebral ischemia
climate change
single cell